Jonathan Gelfond

EBioMedicine · 2023

⊕ Open access · OA

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

▲ 270

Aging Cell · 2019

⊕ Open access · CC-BY

Acarbose improves health and lifespan in aging HET3 mice

▲ 144

Aging Cell · 2015

⊕ Open access · CC-BY

Chronic <scp>mTOR</scp> inhibition in mice with rapamycin alters <scp>T</scp> , <scp>B</scp> , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

▲ 127

Aging Cell · 2011

◌ Citation only

Fat maintenance is a predictor of the murine lifespan response to dietary restriction

▲ 122

PLoS ONE · 2015

⊕ Open access · CC-BY

Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life

▲ 76

Aging Cell · 2022

⊕ Open access · CC-BY

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

▲ 71

Aging · 2016

⊕ Open access · CC-BY

A cross-sectional study of male and female C57BL/6Nia mice suggests lifespan and healthspan are not necessarily correlated

▲ 69

GeroScience · 2023

⊕ Preprint · OA

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

▲ 41

GeroScience · 2024

⊕ Open access · CC-BY

The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride

▲ 11

Nature Communications · 2025

⊕ Open access · CC-BY

Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies

▲ 3

bioRxiv (Cold Spring Harbor Laboratory) · 2024

⊕ Preprint · CC-BY

Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies

▲ 2

The Journals of Gerontology Series A · 2025

⊕ Open access · OA

Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program

▲ 2